🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

68 results for “administered” Clear

  1. A Phase 1, Open-label, Randomized, Crossover Study to Assess the Effect of Different Types of Co-administered Oral Liquids on the Relative Oral Bioavailability of a JNJ 77242113 Tablet Formulation in Healthy Participants.

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial
  2. A Phase 1, Randomized, Placebo-controlled Study with a Double-blind Period with Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients with Alzheimer’s Disease

    Alnylam Netherlands B.V.

    Alzheimer’s Disease

    phase 1 other active

    1 trial
  3. A Phase 1, open label, randomized, 2-sequence, 2-period, crossover, single center study to evaluate the pharmacokinetics of follitropin alfa from 2 manufacturing processes, administered as a single subcutaneous 450 IU dose to pituitary-suppressed healthy premenopausal female participants.

    Merck Sharp and Dohme

    Infertility

    phase 1 other active

    1 trial
  4. A Phase I First Time in Human Open Label Study of GSK3745417 Administered With and Without Anticancer Agents in Participants With Advanced Solid Tumors

    GlaxoSmithKline

    Neoplasms

    phase 1 other active

    1 trial
  5. A Phase I trial to investigate the pharmacokinetics and ECG effects of single doses of linaprazan glurate administered as oral tablets to healthy participants

    Lacuna Pharma Pty Ltd

    Erosive Gastroesophageal Reflux Disease (eGERD)

    phase 1 other active

    1 trial
  6. A Phase I, First In Human, open-label study of escalating doses of INA03 administered intravenously as single agent in adult patients with relapse/refractory Acute Leukemia

    The George Institute

    Relapse/ refractory acute Leukemia

    phase 1 other active

    1 trial
  7. A Phase Ib, Multicentre, Randomised, Single-blind, Parallel-group, Placebo-controlled, Study to Characterise the Pharmacokinetics and Pharmacodynamics of AZD4604 Administered via the Turbuhaler® Device in Adults with Mild Asthma

    AstraZeneca AB

    Asthma

    phase 1 other active

    1 trial
  8. A Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of AZD8630, Administered Once Daily via Inhalation, for 2 Weeks, in Adults with Asthma on Medium-to-high Dose Inhaled Corticosteroids and Long-acting Beta-agonists

    AstraZeneca AB

    Asthma

    phase 1 other active

    1 trial
  9. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants with Systemic Lupus Erythematosus

    Hoffmann-La Roche

    Systemic Lupus Erythematosus (SLE)

    phase 1 other active

    1 trial
  10. A Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of Ascending Intravenous Doses of Glofitamab, Administered after Ocrelizumab Pretreatment, in Patients with Multiple Sclerosis

    Hoffmann-La Roche

    Multiple Sclerosis (MS)

    phase 1 other active

    1 trial
  11. A randomized, open-label, single dose, cross-over study to evaluate the drug-drug interaction between Proscar 5 mg, film-coated tablets and Cialis 5 mg film-coated tablets when co-administered versus the administration of each product alone in healthy volunteers under fasting conditions. Study no. FIN-TAD-DDI-03-24

    Lacuna Pharma Pty Ltd

    healthy male subjects

    phase 1 other active

    1 trial
  12. A randomized, single dose, cross-over bioavailability study comparing the drug-drug interaction between telmisartan tablets, indapamide tablets, and amlodipine tablets when co-administered versus the administration of each product alone in three arms to healthy volunteers under fasting conditions.

    s.r.o.

    high blood pressure

    phase 1 other active

    1 trial
  13. A randomized, single-blind, placebo-controlled, study to examine the safety, tolerability, and pharmacokinetics of M6229 administered as a 120-hour continuous infusion at two dose levels versus placebo in healthy subjects

    Lacuna Pharma Pty Ltd

    Sepsis and Septic Shock

    phase 1 other active

    1 trial
  14. A single-dose, randomized, two-period, two-sequence, crossover comparative bioavailability study on formulations containing ramipril, amlodipine and indapamide in combination product versus Triatec® 10 mg capsules (Sanofi - Produtos Farmacêuticos, Lda., Portugal), containing ramipril, Norvasc® 10 mg, tablets (Upjohn EESV, the Netherlands), containing amlodipine and Natrilix® 2.5 mg film-coated tablets (Les Laboratoires Servier, France), containing indapamide co-administered together as reference in healthy

    Lacuna Pharma Pty Ltd

    hypertension

    phase 1 other active

    1 trial
  15. A study in healthy volunteers to find out how long aticaprant stays in and acts on the body when administered with or without food and with or without fluconazole

    Janssen-Cilag International N.V.

    Healthy Adult Participants

    phase 1 other active

    1 trial
  16. A study in healthy volunteers to find out how long aticaprant stays in and acts on the body when administered with or without rabeprazole.

    Janssen-Cilag International N.V.

    Healthy Adult Participants.

    phase 1 other active

    1 trial
  17. A study to compare the pharmacokinetics of salbutamol administered via metered dose inhalers containing propellants HFA-152a (test) or HFA-134a (reference) in healthy participants aged 18 to 55 inclusive.

    GlaxoSmithKline

    Healthy volunteers

    phase 1 other active

    1 trial
  18. A study to compare the relative potency of salbutamol administered via metered dose inhalers containing propellants HFA-152a to HFA-134a in mild asthmatics aged 18 to 65 inclusive.

    GlaxoSmithKline

    Mild Asthma

    phase 1 other active

    1 trial
  19. A study to evaluate how the body absorbs, breaks down and removes drug as well as safety and tolerability when two drugs are administered together as an injection under the skin to healthy participants.

    Janssen-Cilag International N.V.

    Healthy Volunteers

    phase 1 other active

    1 trial
  20. A three-part trial in healthy volunteers to find out how long icotrokinra stays in and acts on the body when administered as different tablet formulations and under different food conditions

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial
  21. A two-part trial in healthy volunteers to find out how long JNJ-77242113 stays in and acts on the body when administered as different tablet formulations and under different food and water conditions, and to assess the acceptability profile (taste, palatability, and smell) of JNJ-77242113 formulations.

    Janssen-Cilag International N.V.

    Inflammatory Conditions

    phase 1 other active

    1 trial
  22. An Open-label, Single-group, Three-period, Fixed-sequence, Phase I Study to Assess the Pharmacokinetics of AZD6793 Tablets When Administered Alone and in Combination with Itraconazole Capsules in Healthy Adult Female and Male Participants

    AstraZeneca AB

    Chronic obstructive pulmonary disease

    phase 1 other active

    1 trial
  23. An adaptive, randomized, double-blind, single-center, placebo-controlled first-in-human study evaluating safety, tolerability and exposure of single and multiple ascending doses of Lactobacillus expressing CXCL12 administered topically to experimentally induced skin wounds

    Lacuna Pharma Pty Ltd

    Wound healing

    phase 1 other active

    1 trial
  24. An open-label dose escalation study to estimate maximum tolerated dose (MTD), identify dose-limiting toxicities (DLTs) and study pharmacokinetics following a single dose of intracranially administered temozolomide-based SI-053 as an add-on to the current standard of care (SoC), in adult patients with newly diagnosed glioblastoma (GBM).

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources